Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
88568 trials found · Page 113 of 4429
-
New hope for aggressive brain cancer: phase 3 trial launches
Disease control Recruiting nowThe goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main question it aims to answer is: Does niraparib improve overall survival …
Phase: PHASE3 • Sponsor: Ivy Brain Tumor Center • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC
-
Gene therapy trial hopes to restore movement in Parkinson's patients
Disease control Recruiting nowThe objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Phase: PHASE2 • Sponsor: AskBio Inc • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New hope for hodgkin lymphoma patients who Can't have transplants
Disease control Recruiting nowThe prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor. This open label, randomized, phase 2 study aims to evaluate the efficacy of Chidamide+Decitabine plus Anti-PD-1 Antibody and Brentuximab Vedot…
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Apr 24, 2026 16:20 UTC
-
New hope for SMA babies: add-on drug aims to boost motor skills after gene therapy
Disease control Recruiting nowThis is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abepa…
Phase: PHASE4 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
New drug may boost blood cell recovery in kids with bone marrow failure
Disease control Recruiting nowThe purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
New drug could let some colon cancer patients avoid surgery
Disease control Recruiting nowTo learn if cemiplimab can help to control dMMR colon cancer.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New hope for stroke survivors: heart procedure may cut repeat stroke risk
Disease control Recruiting nowAtrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stro…
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New combo therapy targets tough lymphoma cases
Disease control OngoingThe aim of this study was to analyze the safety and efficacy of CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's (B-NHL) lymphoma. The main questions it aims to answer: 1. The safet…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 01, 2026 11:14 UTC
-
New hope for advanced breast cancer: major trial launches
Disease control Recruiting nowThe purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unre…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New bladder cancer device aims to delay surgery in High-Risk patients
Disease control OngoingThe purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radi…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New drug combo aims to keep lung cancer from returning after surgery
Disease control Recruiting nowThis study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior t…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Stroke patients get better recovery with two blood thinners, study finds
Disease control CompletedEarly antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of…
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated May 01, 2026 11:14 UTC
-
Immune cells from your own tumor could fight cervical cancer
Disease control Recruiting nowThis is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
Phase: PHASE2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC
-
New shot could cut bleeding episodes in hemophilia patients
Disease control OngoingThe purpose of this study is to show that KN057 can prevent bleeds in patients with haemophilia A or B without inhibitors and is safe to use. Participants receiving on-demand treatment prior to screening will be randomly assigned to Experimental group or Control group at a ratio …
Phase: PHASE3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 11:12 UTC
-
New Gene-Modified immune cells offer hope for tough lymphoma
Disease control Recruiting nowThe goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational…
Phase: PHASE1, PHASE2 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC
-
New combo therapy may boost survival in advanced anal cancer
Disease control Recruiting nowSquamous cell carcinoma of the anus is still a rare disease but its incidence increases mostly due to its association with human papillomavirus (HPV). When localized, the standard treatment combines radiotherapy and chemotherapy with 5FU and mitomycin-C. Chemoradiotherapy (CRT) a…
Phase: PHASE3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New hope for tough lymphoma: experimental drug takes on standard care in phase 3 trial
Disease control Recruiting nowThis study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has retu…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 01, 2026 11:13 UTC
-
New hope for myeloma: Two-Drug cocktails aim to outsmart relapse
Disease control Recruiting nowThe purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
New trial aims to personalize prostate cancer care with Cutting-Edge scans and genetics
Disease control Recruiting nowThis Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate cancer (PCa). The study contains both a randomized Phase…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research Antwerp • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New hope for endometrial cancer: targeted drug may outperform chemo
Disease control OngoingResearchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical s…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC